USA EDITION
--- VIEWS

Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion

TLN
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion
Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.

Source: WSJ

Share this story
Reader Reactions
Reader Comments
No comments yet. Be the first to comment!
Post a Comment